摘要
目的观察度洛西汀对首发精神分裂症患者认知功能的影响。方法采用随机、双盲对照法,将120例首发精神分裂症患者平均分为研究组(度洛西汀+奋乃静)和观察组(奋乃静+安慰剂)。在治疗前,治疗后4、8、12周末分别以阳性症状和阴性症状量表(PNASS)和副反应量表(TESS)评定疗效和副作用,韦氏记忆量表(WMS)评定治疗前后患者认知功能的改变。结果治疗12周后,研究组的韦氏记忆量表的再认、联想及记忆商(MQ)为:(10.4±2.1)、(11.4±1.9)、(103.6±13.8);观察组分别为(8.9±2.8)、(9.4±2.5)、(91.8±14.9),两组有显著差异(P<0.05)。PANSS总分、阴性因子分及一般精神病理症状分比治疗前明显降低,治疗后4、8、12周末TESS评分,研究组均低于观察组,且治疗后低于治疗前,均有显著性差异(P<0.05)。结论度洛西汀对首发精神分裂症患者认知功能有明显改善,且副作用减少。
Objective To observe the cognition function of duloxetine combined with perphenazine in the treatment of schizophrenia. Methods Being used the vendom control stady, 120 in-patients with chyonic schizophreaia were divided into study gooup （ duloxetine and perphenazine） and control group （ perphenazine and comfort）. Effects and side effects were assessed with PANSS and TESS respectively WMS were evaluated before treatment and after 4,8,12 weeks treatment. Results After treating 12 turnovers, The Wei surname of the research set memory quantity form of again recognize, association of thought and memory company（MQ） is ： （ 10. 4± 2. 1 ）, （ 11.4 ± 1.9 ）, （ 103.6 ±13. 8 ）. The matched control distinguishes for： （ 8.9 ±2. 8 ）, （ 9.4 ± 2. 5 ）, （91.8 ± 14. 9）, two the sets show the difference of high （ P 〈 0.05 ）. The todal scores of PANSS and the scores of negative factor were signficantly decreased with duloxetine and perphenazine. The TESS scores of study group were lower than that of coutrol group after 4,8,12 weeks treatment, and the scores of post-treatment were lower than that of pre-treatment, so there were significant difference between those respectively. Conclusion It suggests that duloxetine combined with perphenazine, could improve distinctly the cognition function of schizoohrenia patients and produce fewer side effects.
出处
《中国实用医药》
2012年第20期1-3,共3页
China Practical Medicine
关键词
精神分裂症
认知功能
度洛西汀
奋乃静
Schizophrenia
Cognition function
Duloxetine
Perphenazine
